Neumora Therapeutics, Inc. (NMRA) — Net Asset Quality Index
Neumora Therapeutics, Inc. (NMRA) has a Net Asset Quality Index of 74.3% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $177.83 Million minus total liabilities of $45.67 Million yields net assets of $132.16 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check NMRA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Neumora Therapeutics, Inc. Net Asset Quality Index Over Time (2020–2024)
This chart shows how Neumora Therapeutics, Inc.'s Net Asset Quality Index has evolved across 5 annual periods from 2020 to 2024. As of September 2025, the index stands at 74.3%, representing net assets of $132.16 Million against total assets of $177.83 Million USD. See NMRA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Neumora Therapeutics, Inc. (2020–2024)
The table below presents the year-by-year Net Asset Quality Index for Neumora Therapeutics, Inc. from 2020 to 2024, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see NMRA market cap.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 90.6% | $287.06 Million | $316.97 Million | $29.91 Million | ▼ -4.0 pp |
| 2023 | 94.5% | $469.08 Million | $496.19 Million | $27.12 Million | ▲ +199.4 pp |
| 2022 | -104.8% | $-446.85 Million | $426.23 Million | $873.08 Million | ▼ -29.1 pp |
| 2021 | -75.8% | $-325.22 Million | $429.30 Million | $754.52 Million | ▼ -28.1 pp |
| 2020 | -47.7% | $-94.38 Million | $197.95 Million | $292.33 Million | — |